CYP2C9 and breast carcinoma: Another study showed that, polymorphisms variants of CYP2C8*2, CYP2C8*3, CYP2C9*2, CYP2C9*3genes showed there was a negative association with therapeutic response towards neo-adjuvant chemotherapy in breast cancer patients[8].